CLOs on the Move

KC Pharmaceuticals

www.kc-ph.com

 
KC Pharmaceuticals is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kc-ph.com
  • 3201 Producer Way
    Pomona, CA USA 91768
  • Phone: 909.598.9499

Executives

Name Title Contact Details

Similar Companies

GeNOsys

GeNOsys (generated nitric oxide systems) Inc. is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas

Mental Health Technologies

MHT is a SaaS company focused on testing and measuring Mental Health & Substance Abuse disorders. We aim to improve healthcare for both patients & providers.

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.

ReactDx

Ambulatory Cardiac Monitoring | Mobile Cardiac Telemetry, Holter, Extended Holter & Wireless Event | Implantable Monitoring Service | Helping physicians add quality years to patients lives, ONE patient at a time.

Oncology Pharma

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the field of oncology, therapeutics and leadership to identify, negotiate and amalgamate “best in class” research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.